Pyxis Oncology, Inc. PYXS 深 滬
已收盤 09-19 16:00:00 美东时间
2.25
-0.070
-3.02%
華盛通- 最 高2.36
- 今 開2.31
- 成交量 86.13万股
- 最 低 2.225
- 昨 收 2.32
- 總市值 1.40亿
- 52周最高 5.3899
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.8332
- 委 比 -56.01%
- 總股本 6201.81万
- 歷史最高 19.00
- 量 比 0.87
- 振 幅 5.82%
- 歷史最低 0.8332
- 每 手 1
- 風險率 0.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Guggenheim Initiates Coverage On Pyxis Oncology with Buy Rating, Announces Price Target of $5
Guggenheim analyst Brad Canino initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Buy rating and announces Price Target of $5.
09-04 21:54
Pyxis Oncology to Participate in September Investor and Industry Conferences
Pyxis Oncology announced that President and CEO Lara S. Sullivan will attend the 2025 Cantor Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference in September, participating in fireside chats and investor meetings. She will also present at the 2nd Annual ADC and Novel Conjugates Summit in Boston. Live webcasts of the Cantor and H.C. Wainwright events will be available on Pyxis Oncology’s website. The company f...
08-21 11:30
Pyxis Oncology Q2 EPS $(0.30) Beats $(0.35) Estimate, Sales $2.82M
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.35) by 14.77 percent. This is a 3.45 percent decrease over losses of $(0.29) per share from the
08-15 04:36
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
Pyxis Oncology reported Q2 2025 financial results, including $2.8 million milestone revenue from suvemcitug's approval in China. They are advancing MICVO's Phase 1 monotherapy and Phase 1/2 combination studies with KEYTRUDA. The company has $90.4 million in cash, expecting to fund operations through 2026. R&D expenses rose due to MICVO-related costs, leading to a net loss of $18.4 million.
08-14 20:05
Pyxis Oncology Updates Enrollment for Phase 1 Trial of New Cancer Drug Micvo
On July 31, 2025, revisions to patient enrollment participants related to Pyxis Oncology, Inc.'s (the "Company") Phase 1 monotherapy clinical trial to evaluate micvotabart pelidotin ("MICVO", formerly PYX-201) were made
08-04 19:29
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 30, 2025 – Pyxis Oncology granted stock options to purchase 246,238 shares to four new employees under its 2022 Inducement Plan. The options have a $1.10 exercise price, with 181,238 shares vesting over four years and 65,000 shares vesting by December 31, 2025. Pyxis Oncology is a clinical-stage company developing innovative treatments for difficult cancers, focusing on its lead candidate, micvotabart pelidotin (MICVO), currently in ...
06-30 20:30
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
05-20 09:28
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $5 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $5 price target.
05-19 18:55
美股大行评级 | Compass Point：上调Affirm Holdings评级至"买入"，目标价从61美元升至64美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1109399410911752193.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Femasys Inc Ordinary Shares(FEMY)"买入"评级，目标价从12美元升至15美元</p> <p>• HC Wainwright & C
03-20 09:49
Pyxis Oncology Advances Cancer Therapeutics with MICVO
Pyxis Oncology, Inc. ( ($PYXS) ) has released its Q4 earnings. Here is a breakd...
03-19 11:55
